# The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours.

> PubMed lists PMID 8813476 in Digestion as Clinical Trial, Journal Article, Multicenter Study, with publication-date metadata of 1996 (year precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-8813476-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-02-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-8813476-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-8813476-lanreotide-v1.json
- Content SHA-256: `0ce4a1b8151951dfcae0d9bed8004b4054e88605274bdc363d63e1406dbcf699`

## Claims and source pins

### Headline

The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours. ([`pubmed-observation-pmid-8813476-2018-02-16-d4200e746a01`](#source-pubmed-observation-pmid-8813476-2018-02-16-d4200e746a01))

### Summary

PubMed lists PMID 8813476 in Digestion as Clinical Trial, Journal Article, Multicenter Study, with publication-date metadata of 1996 (year precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8813476-2018-02-16-d4200e746a01`](#source-pubmed-observation-pmid-8813476-2018-02-16-d4200e746a01))

### Paragraph 1

PubMed lists PMID 8813476 in Digestion as Clinical Trial, Journal Article, Multicenter Study, with publication-date metadata of 1996 (year precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8813476-2018-02-16-d4200e746a01`](#source-pubmed-observation-pmid-8813476-2018-02-16-d4200e746a01))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-8813476-2018-02-16-d4200e746a01`](#source-pubmed-observation-pmid-8813476-2018-02-16-d4200e746a01))

## Sources

<a id="source-pubmed-observation-pmid-8813476-2018-02-16-d4200e746a01"></a>
- **The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours. · retained source version 1:2018-02-16:current:d4200e746a01c9a70fd14d7e9637543607bf5159be679c4e6c89ac3de5cc165a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/8813476/) (`pubmed-observation-pmid-8813476-2018-02-16-d4200e746a01`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-8813476-lanreotide-v1.json SHA-256: 0ce4a1b8151951dfcae0d9bed8004b4054e88605274bdc363d63e1406dbcf699.